Recently, the State Council executive meeting decided to reduce the import tariffs on all common drugs including anticancer drugs, alkaloid drugs with anticancer effects, and Chinese patent medicines with actual imports from zero on May 1 this year. Realize zero tariffs on all anticancer drugs actually imported from China. Significantly reduce the VAT tax on the production and import of anticancer drugs. Zeng Huihui, a professor at Peking University School of Pharmacy, said in an interview with this reporter that "this is a pragmatic benefit-minded initiative." Multi-pronged measures to promote the price reduction of anticancer drugs "Anti-cancer" is a serious challenge for Chinese medical care . Zeng Huihui pointed out: "The incidence of cancer in China is relatively high. The early detection of cancer in developed countries is also better, and many cancer patients in China are already in the middle and late stages of the disease." The 2017 China Cancer Registration Annual Report data shows that China is new every year. The number of cancer cases was 4.29 million. In this context, the market for anticancer drugs in China exceeds 100 billion yuan, and about half of them rely on imports. In fact, the tariffs on imported anticancer drugs are not high in the price. According to the Ministry of Finance's 2017 tax rate data, the MFN rate for Chinese imports is only 2% to 4%, and the entry into sales requires a 17% VAT. Therefore, in the newly launched series of measures, the combination of “zero tariff†and “larger reduction of value-added tax†will truly achieve the goal of benefiting the people. "A comprehensive consideration of various measures, the policy introduced this time will reduce the price of imported anti-cancer drugs by at least 20%." Shi Luwen, director of the Center for International Studies in Pharmaceutical Management of Peking University, said. Domestic pharmaceutical companies need to strengthen independent research and development Previously, the existence of tariffs protected the domestic similar enterprises to a certain extent. Zheng Shanhai, a doctor at the Coal General Hospital, believes that “zero tariffs†reflect China’s efforts to catch up with the pace and modest learning attitude. "The reduction of tariffs is a signal for the foreign pharmaceutical industry to open its doors. It is equivalent to giving the other party a position to pay attention to the Chinese market from a policy perspective. It will also give birth to the other party's strategy of changing prices to the market to some extent. Low drug prices." "Zero Tariff" may also have a certain impact on domestic pharmaceutical companies while reducing the price of medicines. Zeng Huihui pointed out that many anti-cancer drug manufacturers in China are still in the initial stage. "This kind of shock is also a matter to be faced sooner or later." Zeng Huihui believes that it is necessary to let the people use the cheaper anticancer drugs faster and better to prevent poverty due to illness, or to rely on themselves to encourage the research and development of domestic anticancer drugs. Accelerate the importation of innovative drugs In addition to promoting the price of anticancer drugs, so that more patients can "available" drugs, more patients should be "use" drugs. Previously, China's import of anti-cancer drugs approval process was long, resulting in the domestic market is slower than foreign countries. In response to this problem, the new policy proposes to speed up the import and marketing of innovative drugs. The clinical trial application was changed from the approval system to the default system, and the imported chemical drugs were changed to the customs inspection results, and the batch inspection was no longer carried out batch by batch. The new policy also emphasizes strengthening intellectual property protection. A data protection period of up to 6 years for innovative chemical drugs is set, and the same varieties are not approved for listing during the protection period. Compensation for patent protection period of up to 5 years for innovative drugs that are simultaneously applied for listing in China and abroad. Shi Luwen believes that these measures will promote shortening the time for approval of imported drugs, reduce the time cost of pharmaceutical companies, help attract international leading anticancer drugs into the Chinese market, and solve the problem of difficulty in using drugs. (People's Daily) low speed handpiece,dental low speed handpiece,low speed dental handpiece Foshan Ja Suo Medical Device Co., LTD , https://www.jasuodental.com